Medovex has priced its initial public offering of 1,391,305 units, each unit consisting of one share of common stock and one Series A Warrant, at a price to the public of $5.75 per unit.
The units are expected to begin trading on The NASDAQ Capital Market on December 19, 2014 under the ticker symbol "MDVXU."
Searching for more deal information? Current Partnering offers the following options:
|
The closing of the offering is expected to occur on December 24, 2014, subject to customary closing conditions.
Medovex intends to use the net proceeds it receives from the offering to fund its clinical trials and product development, related regulatory expenses, and general administrative expenses, and for general working capital purposes.
For further deal information visit Current Agreements (subscription required)
Related
Scorecard: Top partnering deals by value in 2014
View: Top pharmaceutical companies
View: Top biotech companies
Report: Top 50 Big Pharma Partnering and M&A Deal Trends
Report: Top 50 Big Biotech Partnering and M&A Deal Trends
Browse: Complete Current Partnering report catalog
